Diabetes Meletus type 2. Type 2 diabetes mellitus with other specified complications
Conditions
Interventions
Intervention 1: Intervention group: Patients with inclusion criteria will be treated with 10 mg empagliflozin (From Abidi Pharmaceutical Company) for 24 weeks along with their other drugs. Patients wi
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients without a history of taking SGLT2 inhibitors for at least the past 12 weeks Patients with no history of insulin use HbA1c >6.2 9.5 >regardless of diet, exercise, and medical treatment other than SGLT2 inhibitors and insulin Insulin resistance (HOMA-IR > 1.73 (homeostatic model assessment of insulin resistance
Exclusion criteria
Exclusion criteria: Patient unwillingness to participate in the study Sensitivity to empagliflozin Use of anti-inflammatory drugs within the past three months GFR <40 Pregnancy or breastfeeding History of cancer History of recurrent urinary tract infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High sensitive C-reactive protein. Timepoint: Before the start of the intervention and 3 months and 6 months after starting empagliflozin. Method of measurement: Demeditec brand laboratory kit.;IL-6. Timepoint: Before the start of the intervention and 3 months and 6 months after starting empagliflozin. Method of measurement: Demeditec brand laboratory kit.;Fasting blood insulin level. Timepoint: Before the start of the intervention and 3 months and 6 months after starting empagliflozin. Method of measurement: Biomed brand laboratory kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| HOMA index. Timepoint: En Before the start of the intervention and 3 months and 6 months after starting empagliflozin. Method of measurement: HOMA index formula. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVajieheh Chavoshi
Kashan University of Medical Sciences
Outcome results
None listed